International Journal of Pharmacology1811-77751812-5700Asian Network for Scientific Information10.3923/ijp.2015.944.955MontesDante Aviles-RuizMaribel Herrera-RamosRuben Roman-FerrerEnrique Jimenez-CortazarManases Gonzalez-ZamilpaAlejandro TortorielloJaime 82015118Galphimia glauca is a plant species that has been used in mexican traditional Medicine for the treatment of central nervous system disorders. It was demonstrated that the standardized extract of G. glauca, by means of double-blind, controlled and randomized clinical studies, possesses therapeutic effectiveness in patients with generalized anxiety disorder. In the active extract, nor-secotriterpenes Galphimines, Galphimine-A (G-A) and Galphimine-B (G-B) are prominent for their anxiolytic effect. In the present work, the oral administration of different doses of G-A in ICR male mice submitted to the Elevated Plus Maze (EPM) test was capable of inducing a significant anxiolytic effect, while any of the doses modified the spontaneous motor activity of the mice in the Open Field Test (OFT). The administration of G-A (30 mg kg1, p.o.) in mice inhibited the anxiogenic effect of picrotoxin (PTX, 2 mg kg1, i.p.), but not of bicuculline (BCC, 5 mg kg1, i.p.) and pentylenetetrazole (PTZ, 10 mg kg1, i.p.) in the EPM. The combination of G-A with these drugs was evaluated by means of in vivo extracellular recordings in basolateral amygdala (BLA). A dose-dependent increase of the firing rate on BLA neurons was induced by the administration (i.v.) of different doses of G-A, while diazepam (DZP) decreased the firing rate. The co-administration of G-A with DZP or flumazenil (FMZ) did not modify the effect produced by these drugs on the firing rate. However, the co-administration of G-A modified the effect produced by PTX. The G-A was able to produce an anxiolytic effect when administered at different doses orally in mice, without inducing an associated sedative effect. Electrophysiological recordings showed that the effect produced by G-A is different of that of DZP and suggest that G-A do not interact directly with the GABAergic system (transmission mechanism for the g-aminobutyric acid-GABA), while it was able to modify the effect produced by PTX, BCC and Phaclofen evidencing a different action mechanism.]]>Aitkenhead, A.R., G. Smith and D.J. Rowbotham,20072007pp: 192-200pp: 192-200Archer, J.,197321205235Cannistraro, P.R. and S.L. Rauch,200337825Cavallini, M. and L. Bellodi,20012001pp: 25-40pp: 25-40Clement, Y. and G. Chapouthier,199822623633Clenet, F., M. Hascoet, G. Fillion, H. Galons and M. Bourin,2005158339348Choleris, E., A.W. Thomas, M. Kavaliers and F.S. Prato,200125235260Das, P., C.L. Bell-Horner, T.K. Machu and G.H. Dillon,2003A receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors.]]>44431438Davis, M.,19984412391247Davis, M., D. Rainnie and M. Cassell,199417208214Gaudreau, H. and D. Pare,19967513011315Gonzalez-Cortazar, M., J. Tortoriello and L. Alvarez,200571711716Herrera-Arellano, A., E. Jimenez-Ferrer, A. Zamilpa, M. Morales-Valdez, C.E. Garcia-Valencia and J. Tortoriello,2007Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.]]>73713717Herrera-Arellano, A., J.E. Jimenez-Ferrer, A. Zamilpa, G. Garcia-Alonso, S. Herrera-Alvarez and J. Tortoriello,2012Galphimia glauca vs. lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial.]]>7815291535Herrera-Ruiz, M., M. Gonzalez-Cortazar, E. Jimenez-Ferrer, A. Zamilpa, L. Alvarez, G. Ramirez and J. Tortoriello,2006Galphimia glauca and their chemical derivatives.]]>695961Herrera-Ruiz, M., J.E. Jimenez-Ferrer, T.C.M. de Lima, D. Aviles-Montes, D. Perez-Garcia, M. Gonzalez-Cortazar and J. Tortoriello,2006Galphimia glauca.]]>132328Hodges, H., S. Green and B. Glenn,198792491504Jimenez-Ferrer, E., M. Herrera-Ruiz, R. Ramirez-Garcia, A. Herrera-Arellano and J. Tortoriello,2011137724729Klodzinska, A., E. Tatarczynska, E. Chojnacka-Wojcik, G. Nowak, N.D.P. Cosford and A. Pilc,2004A signaling.]]>47342350LeDoux, J.,200323727738Lister, R.G.,198792180185McDonald, A.J.,199855257332Pape, H.C. and D. Pare,201090419463Pare, D. and D.R. Collins,20002027012710Paxinos, G. and C. Watson,19862nd Edn.,Pellow, S., P. Chopin, S.E. File and M. Briley,198514149167Pellow, S. and S.E. File,198624525529Prieto-Gomez, B., J. Tortoriello, A. Vazquez-Alvarez and C. Reyes-Vazquez,2003693843Siemiatkowski, M., H. Sienkiewicz-Jarosz, A.I. CzLonkowska, A. Bidzinski and A. Plaznik,20003H]muscimol binding after buspirone pretreatment.]]>66645651Stankevicius, D., E.C. Rodrigues-Costa, J.C. Florio and J. Palermo-Neto,200854300308Sun, Y.N., L.B. Li, Q.J. Zhang, Y.P. Hui and Y. Wang et al.,20132A/2C receptor activation is decreased in rats with 6-hydroxydopamine lesions.]]>73404414Tortoriello, J. and A. Ortega,1993Galphimia glauca.]]>59398400Tortoriello, J., A. Ortega, M. Herrera-Ruiz, J. Trujillo and C. Reyes-Vazquez,199864309313Vissiennon, C., K. Nieber, O. Kelber and V. Butterweck,201223733740Zhang, Z.J.,20047516591699Bousono, M.A., M.T. Bascaron and J. Bobes,20092009pp: 275-290pp: 275-290